A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer

BACKGROUND: Our randomized controlled clinical trial will explore the potential of bazedoxifene plus conjugated estrogen to modulate breast tissue-based risk biomarkers as a surrogate for breast cancer risk reduction. This paper investigates the statistical design features of the trial and the ratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Gajewski, Byron J., Kimler, Bruce F., Koestler, Devin C., Mudaranthakam, Dinesh Pal, Young, Kate, Fabian, Carol J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721008/
https://www.ncbi.nlm.nih.gov/pubmed/36471449
http://dx.doi.org/10.1186/s13063-022-06930-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721008/
https://www.ncbi.nlm.nih.gov/pubmed/36471449
http://dx.doi.org/10.1186/s13063-022-06930-5

Ejemplares similares